{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:27:03Z","timestamp":1777418823340,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10072-019-04196-5","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T15:54:30Z","timestamp":1576684470000},"page":"783-787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cannabinoids and dystonia: an issue yet to be defined"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9028-5972","authenticated-orcid":false,"given":"Marcello Mario","family":"Mascia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Carmagnini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Defazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"4196_CR1","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1097\/j.pain.0000000000001293","volume":"159","author":"E Stockings","year":"2018","unstructured":"Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, Murnion B, Farrell M, Weier M, Degenhardt L (2018) Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain 159:1932\u20131954. https:\/\/doi.org\/10.1097\/j.pain.0000000000001293","journal-title":"Pain"},{"key":"4196_CR2","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1212\/01.wnl.0000455935.13606.91","volume":"83","author":"S Wright","year":"2014","unstructured":"Wright S, Yadav V, Bever C Jr, Bowen J, Bowling A, Weinstock-Guttman B, Cameron M, Bourdette D, Gronseth GS, Narayanaswami P (2014) Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 83:1484\u20131486. https:\/\/doi.org\/10.1212\/01.wnl.0000455935.13606.91","journal-title":"Neurology"},{"key":"4196_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/WCO.0000000000000660","volume":"32","author":"S Billakota","year":"2019","unstructured":"Billakota S, Devinsky O, Marsh E (2019) Cannabinoid therapy in epilepsy. Curr Opin Neurol 32:220\u2013226. https:\/\/doi.org\/10.1097\/WCO.0000000000000660","journal-title":"Curr Opin Neurol"},{"key":"4196_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3233\/BEN-120276","volume":"27","author":"KR M\u00fcller-Vahl","year":"2013","unstructured":"M\u00fcller-Vahl KR (2013) Treatment of Tourette syndrome with cannabinoids. Behav Neurol 27:119\u2013124. https:\/\/doi.org\/10.3233\/BEN-120276","journal-title":"Behav Neurol"},{"key":"4196_CR5","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/head.12570","volume":"55","author":"EP Baron","year":"2015","unstructured":"Baron EP (2015) Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it\u2019s been \u2026. Headache 55:885\u2013916. https:\/\/doi.org\/10.1111\/head.12570","journal-title":"Headache"},{"key":"4196_CR6","first-page":"211","volume-title":"Therapy with botulinum toxin","author":"ES Consky","year":"1994","unstructured":"Consky ES, Lang AE (1994) Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M (eds) Therapy with botulinum toxin, 1st edn. Marcel Dekker, New York, pp 211\u2013238","edition":"1"},{"key":"4196_CR7","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/mds.870120414","volume":"12","author":"CL Comella","year":"1997","unstructured":"Comella CL, Stebbins GT, Goetz CG, Chmura TA, Bressman SB, Lang AE (1997) Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov Disord 12:570\u2013575. https:\/\/doi.org\/10.1002\/mds.870120414","journal-title":"Mov Disord"},{"key":"4196_CR8","first-page":"81","volume-title":"Disorders of movement, current status of modern therapy","author":"CD Marsden","year":"1981","unstructured":"Marsden CD (1981) Treatment of torsion dystonia. In: Barbeau A (ed) Disorders of movement, current status of modern therapy. Lippincott, Philadelphia, pp 81\u2013104"},{"key":"4196_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0885-3924(02)00426-8","volume":"24","author":"A Chatterjee","year":"2002","unstructured":"Chatterjee A, Almahrezi A, Ware M, Fitzcharles MA (2002) A dramatic response to inhaled cannabis in a woman with central thalamic pain and dystonia. J Pain Symptom Manag 24:4\u20136. https:\/\/doi.org\/10.1016\/S0885-3924(02)00426-8","journal-title":"J Pain Symptom Manag"},{"key":"4196_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/mds.20268","volume":"20","author":"MC Uribe Roca","year":"2005","unstructured":"Uribe Roca MC, Micheli F, Viotti R (2005) Cannabis sativa and dystonia secondary to Wilson\u2019s disease. Mov Disord 20:113\u2013115. https:\/\/doi.org\/10.1002\/mds.20268","journal-title":"Mov Disord"},{"key":"4196_CR11","first-page":"45","volume":"25","author":"B Gauter","year":"2004","unstructured":"Gauter B, Rukwied R, Konrad C (2004) Cannabinoid agonists in the treatment of blepharospasm \u2013 a case report study. Neuro Endocrinol Lett 25:45\u201348","journal-title":"Neuro Endocrinol Lett"},{"key":"4196_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/01658107.2017.1318150","volume":"41","author":"PM Radke","year":"2017","unstructured":"Radke PM, Mokhtarzadeh A, Lee MS, Harrison AR (2017) Medical cannabis, a beneficial high in treatment of blepharospasm? An early observation. Neuroophthalmology 41:253\u2013258. https:\/\/doi.org\/10.1080\/01658107.2017.1318150","journal-title":"Neuroophthalmology"},{"key":"4196_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3109\/00207458608985678","volume":"30","author":"P Consroe","year":"1986","unstructured":"Consroe P, Sandyk R, Snider SR (1986) Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30:277\u2013282. https:\/\/doi.org\/10.3109\/00207458608985678","journal-title":"Int J Neurosci"},{"key":"4196_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/mds.1280","volume":"17","author":"SH Fox","year":"2002","unstructured":"Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM (2002) Randomised, double-blind, placebo -controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17:145\u2013149. https:\/\/doi.org\/10.1002\/mds.1280","journal-title":"Mov Disord"},{"key":"4196_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.baga.2011.04.002","volume":"1","author":"C Zadikoff","year":"2011","unstructured":"Zadikoff C, Wadia PM, Miyasaki J, Chen R, Lang AE, So J, Fox SH (2011) Cannabinoid, CB1 agonists in cervical dystonia: failure in a phase IIa randomized controlled trial. Basal Ganglia 1:91\u201395. https:\/\/doi.org\/10.1016\/j.baga.2011.04.002","journal-title":"Basal Ganglia"},{"key":"4196_CR16","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/mds.20214","volume":"19","author":"HC Jabusch","year":"2004","unstructured":"Jabusch HC, Schneider U, Altenm\u00fcller E (2004) Delta9-tetrahydrocannabinol improves motor control in a patient with musician\u2019s dystonia. Mov Disord 19:990\u2013991. https:\/\/doi.org\/10.1002\/mds.20214","journal-title":"Mov Disord"},{"key":"4196_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/mds.10671","volume":"19","author":"HC Jabusch","year":"2004","unstructured":"Jabusch HC, Vauth H, Altenm\u00fcller E (2004) Quantification of focal dystonia in pianists using scale analysis. Mov Disord 19:171\u2013180. https:\/\/doi.org\/10.1002\/mds.10671","journal-title":"Mov Disord"},{"key":"4196_CR18","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.parkreldis.2015.08.036","volume":"22","author":"M Hallett","year":"2016","unstructured":"Hallett M (2016) Functional (psychogenic) movement disorders \u2013 clinical presentations. Parkinsonism Relat Disord 22:S149\u2013S152. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.08.036","journal-title":"Parkinsonism Relat Disord"},{"key":"4196_CR19","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/mds.25475","volume":"28","author":"A Albanese","year":"2013","unstructured":"Albanese A, Bhatia K, Bressman SB, DeLong MR, Fahn S, Fung VS, Hallett M, Joseph J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK (2013) Phenomenology and classification of dystonia: a consensus update. Mov Disord 28:863\u2013873. https:\/\/doi.org\/10.1002\/mds.25475","journal-title":"Mov Disord"},{"key":"4196_CR20","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.clinph.2009.06.015","volume":"120","author":"M Tinazzi","year":"2009","unstructured":"Tinazzi M, Squintani G, Berardelli A (2009) Does neurophysiological testing provide information we need to improve the clinical management of primary dystonia? Clin Neurophysiol 120:1424\u20131432. https:\/\/doi.org\/10.1016\/j.clinph.2009.06.015","journal-title":"Clin Neurophysiol"},{"key":"4196_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/B978-0-12-801772-2.00020-5","volume":"139","author":"DA Schmerler","year":"2016","unstructured":"Schmerler DA, Espay AJ (2016) Functional dystonia. Handb Clin Neurol 139:235\u2013245. https:\/\/doi.org\/10.1016\/B978-0-12-801772-2.00020-5","journal-title":"Handb Clin Neurol"},{"key":"4196_CR22","doi-asserted-by":"publisher","unstructured":"Mainka T, Erro R, Rothwell J, K\u00fchn AA, Bhatia KP, Ganos C (2019) Remission in dystonia - systematic review of the literature and meta-analysis. Parkinsonism Relat Disord. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.02.020","DOI":"10.1016\/j.parkreldis.2019.02.020"},{"key":"4196_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/cpt.563","volume":"101","author":"R Le Boisselier","year":"2017","unstructured":"Le Boisselier R, Alexandre J, Lelong-Boulouard V, Debruyne D (2017) Focus on cannabinoids and synthetic cannabinoids. Clin Clin Pharmacol Ther 101:220\u2013229. https:\/\/doi.org\/10.1002\/cpt.563","journal-title":"Clin Clin Pharmacol Ther"},{"key":"4196_CR24","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/bph.13215","volume":"173","author":"C Garc\u00eda","year":"2016","unstructured":"Garc\u00eda C, Palomo-Garo C, G\u00f3mez-G\u00e1lvez Y, Fern\u00e1ndez-Ruiz J (2016) Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. Br J Pharmacol 173:2069\u20132079. https:\/\/doi.org\/10.1111\/bph.13215","journal-title":"Br J Pharmacol"},{"key":"4196_CR25","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0024-3205(99)00293-3","volume":"65","author":"MC Sa\u00f1udo-Pe\u00f1a","year":"1999","unstructured":"Sa\u00f1udo-Pe\u00f1a MC, Tsou K, Walker JM (1999) Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 65:703\u2013713. https:\/\/doi.org\/10.1016\/S0024-3205(99)00293-3","journal-title":"Life Sci"},{"key":"4196_CR26","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1124\/pr.110.003004","volume":"62","author":"RG Pertwee","year":"2010","unstructured":"Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62:588\u2013631. https:\/\/doi.org\/10.1124\/pr.110.003004","journal-title":"Pharmacol Rev"},{"key":"4196_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/bs.apha.2017.05.003","volume":"80","author":"K Starowicz","year":"2017","unstructured":"Starowicz K, Finn DP (2017) Cannabinoids and pain: sites and mechanisms of action. Adv Pharmacol 80:437\u2013475. https:\/\/doi.org\/10.1016\/bs.apha.2017.05.003","journal-title":"Adv Pharmacol"},{"key":"4196_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-20825-1_1","volume":"231","author":"RG Pertwee","year":"2015","unstructured":"Pertwee RG (2015) Endocannabinoids and their pharmacological actions. Handb Exp Pharmacol 231:1\u201337. https:\/\/doi.org\/10.1007\/978-3-319-20825-1_1","journal-title":"Handb Exp Pharmacol"},{"key":"4196_CR29","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S1474-4422(19)30032-8","volume":"18","author":"D Friedman","year":"2019","unstructured":"Friedman D, French JA, Maccarrone M (2019) Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders. Lancet Neurol 18:504\u2013512. https:\/\/doi.org\/10.1016\/S1474-4422(19)30032-8","journal-title":"Lancet Neurol"},{"key":"4196_CR30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.tips.2015.02.008","volume":"36","author":"M Maccarrone","year":"2015","unstructured":"Maccarrone M, Bab I, B\u00edr\u00f3 T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, Pacher P, Sharkey KA, Zimmer A (2015) Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 36:277\u2013296. https:\/\/doi.org\/10.1016\/j.tips.2015.02.008","journal-title":"Trends Pharmacol Sci"},{"key":"4196_CR31","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/mds.25579","volume":"28","author":"A Albanese","year":"2013","unstructured":"Albanese A, Sorbo FD, Comella C, Jinnah HA, Mink JW, Post B, Vidailhet M, Volkmann J, Warner TT, Leentjens AF, Martinez-Martin P, Stebbins GT, Goetz CG, Schrag A (2013) Dystonia rating scales: critique and recommendations. Mov Disord 28:874\u2013883. https:\/\/doi.org\/10.1002\/mds.25579","journal-title":"Mov Disord"},{"key":"4196_CR32","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/mds.26156","volume":"30","author":"G Defazio","year":"2015","unstructured":"Defazio G, Hallett M, Jinnah HA, Stebbins GT, Gigante AF, Ferrazzano G, Conte A, Fabbrini G, Berardelli A (2015) Development and validation of a clinical scale for rating the severity of blepharospasm. Mov Disord 30:525\u2013530. https:\/\/doi.org\/10.1002\/mds.26156","journal-title":"Mov Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-019-04196-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-019-04196-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-019-04196-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:53:14Z","timestamp":1608079994000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-019-04196-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["4196"],"URL":"https:\/\/doi.org\/10.1007\/s10072-019-04196-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]},"assertion":[{"value":"2 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}